Two-Year Data From TRILUMINATE Pivotal Study Presented for Abbott’s TriClip TEER System

March 31, 2025—Abbott announced late-breaking data from its TRILUMINATE pivotal trial of the TriClip transcatheter edge-to-edge repair (TEER) system to treat tricuspid regurgitation (TR).

Teleflex’s Ringer PBC Studied for Management of Coronary Perforations

March 31, 2025—Teleflex Incorporated announced preliminary results from its Ringer perfusion balloon catheter (PBC) investigational device exemption (IDE) study.

One-Year Patient Outcomes Presented for Anteris DurAVR THV

March 31, 2025—Anteris Technologies Global Corp.

Medtronic’s Evolut TAVR System Evaluated in Low-Risk Patients at 5 Years

March 30, 2025—Medtronic announced 5-year outcomes from the Evolut Low-Risk Trial.

Impulse Dynamics Optimizer Smart Mini System Receives Expanded Indication in Europe

March 28, 2025—Impulse Dynamics plc announced that it received European CE Mark approval for an expanded indication for its Optimizer Smart Mini system, which delivers the company’s cardiac contractility modulation (CCM) therapy.

Elucid Names Dr. Amir Ahmadi as a Chief Scientific Advisor

March 27, 2025—Elucid recently announced that cardiologist Amir Ahmadi, MD, has joined as a Chief Scientific Advisor and will lead the company’s clinical strategy.

GE HealthCare Launches Flyrcado Injection to Treat CAD

March 27, 2025—GE HealthCare announced the United States launch of Flyrcado (flurpiridaz F 18) injection, which received FDA approval in 2024 for patients with known or suspected coronary artery disease.

Vasorum’s Celt ACD Plus Vascular Closure Device Approved by FDA

March 27, 2025—Vasorum USA, Inc. announced FDA approval of the Celt ACD Plus system, which is designed for rapid arterial puncture closure after percutaneous catheter-based vascular procedures.

Supira Medical Closes Series E Financing to Support pVAD System

March 26, 2025—Supira Medical, Inc. announced that it completed a $120 million Series E financing round.

Evident Vascular Closes Additional Financing for AI-Powered IVUS Platform

March 25, 2025—Evident Vascular, Inc., developer of an intravascular ultrasound (IVUS) platform powered by artificial intelligence and designed to optimize vascular imaging for peripheral and coronary interventions, announced it closed its Series B financing with new investors.